651 related articles for article (PubMed ID: 26254349)
1. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Nukatsuka M; Nakagawa F; Saito H; Sakata M; Uchida J; Takechi T
Anticancer Res; 2015 Mar; 35(3):1437-45. PubMed ID: 25750295
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.
Tsukihara H; Nakagawa F; Sakamoto K; Ishida K; Tanaka N; Okabe H; Uchida J; Matsuo K; Takechi T
Oncol Rep; 2015 May; 33(5):2135-42. PubMed ID: 25812794
[TBL] [Abstract][Full Text] [Related]
4. Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.
Suzuki N; Nakagawa F; Matsuoka K; Takechi T
Oncol Rep; 2016 Dec; 36(6):3123-3130. PubMed ID: 27805254
[TBL] [Abstract][Full Text] [Related]
5. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
7. TAS-102 for the treatment of metastatic colorectal cancer.
Salvatore L; Rossini D; Moretto R; Cremolini C; Schirripa M; Antoniotti C; Marmorino F; Loupakis F; Falcone A; Masi G
Expert Rev Anticancer Ther; 2015; 15(11):1283-92. PubMed ID: 26509228
[TBL] [Abstract][Full Text] [Related]
8. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.
Limagne E; Thibaudin M; Nuttin L; Spill A; Derangère V; Fumet JD; Amellal N; Peranzoni E; Cattan V; Ghiringhelli F
Cancer Immunol Res; 2019 Dec; 7(12):1958-1969. PubMed ID: 31611243
[TBL] [Abstract][Full Text] [Related]
9. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
[TBL] [Abstract][Full Text] [Related]
10. TAS-102: a novel antimetabolite for the 21st century.
Uboha N; Hochster HS
Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466
[TBL] [Abstract][Full Text] [Related]
11. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
[TBL] [Abstract][Full Text] [Related]
12. A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
Miyamoto Y; Lenz HJ; Baba H
Expert Rev Clin Pharmacol; 2016; 9(3):355-65. PubMed ID: 26677869
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
Sawada N; Kondoh K; Mori K
Oncol Rep; 2007 Oct; 18(4):775-8. PubMed ID: 17786335
[TBL] [Abstract][Full Text] [Related]
14. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
Nukatsuka M; Saito H; Sakamoto K; Nakagawa F; Uchida J; Kobunai T; Shiraishi K; Takechi T
Anticancer Res; 2012 Jul; 32(7):2807-12. PubMed ID: 22753741
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil.
Becerra CR; Yoshida K; Mizuguchi H; Patel M; Von Hoff D
J Clin Pharmacol; 2017 Jun; 57(6):751-759. PubMed ID: 28070894
[TBL] [Abstract][Full Text] [Related]
20. [
Kim SY; Jung JH; Lee HJ; Soh H; Lee SJ; Oh SJ; Chae SY; Lee JH; Lee SJ; Hong YS; Kim TW; Moon DH
Cancer Res; 2017 Dec; 77(24):7120-7130. PubMed ID: 29055019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]